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Comprehensive Chronic Pain Treatment: Does Smoking Affect Outcomes?
Abstract
Abstract
Objective: To determine whether smoking status effects pain and functional outcomes in a chronic pain
program.
Methods: A retrospective cohort study of 178 patients treated at the Nebraska Medicine comprehensive
Pain Management Program over a five year period was completed. Outcomes measures were the Visual
Analog Scale Past Month Average Pain score (VAS-PMA), Multidimensional Pain Inventory pain and
interference scales (MPI-P and MPI-I), and the Pain and Impairment Relationship Scale (PAIRS). Patients
were categorized by smoking status into non-smoker or current smoker groups. Wilcoxon tests were used
to compare the pre scores, post scores, and post-minus-pre scores between smoking status groups.
Results: The pre-treatment VAS-PMA and MPI-P median scores were significantly higher in the current
smoker group (81.5 and 5.0, respectively) compared to the non-smoker group (76.5 and 4.3, respectively),
whereas post-treatment median scores did not differ. Furthermore, the current smoker group had a
significantly greater decrease on the MPI-P from pre- to post-treatment (median=-2.0) than the nonsmoker group (median=-1.6). In addition, smokers had a significantly higher pre-treatment PAIRS score
(73.5) than nonsmokers (70), whereas post-treatment scores did not differ.
Conclusion: Smokers and non-smokers both benefit from the program, but smokers, who report greater
initial pain and stronger beliefs about the association between pain and functional impairment, may
benefit more than non-smokers.
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Abstract
Introduction: Comprehensive pain programs
are important for helping patients who have
found little relief for their pain with other
treatment modalities. It is important to know
what factors affect the success of the program
and who should be referred to the program.
This study seeks to determine whether
smoking status affects pain and functional
outcomes in a chronic pain program.
Methods: A retrospective cohort study of
178 patients treated at the Nebraska Medicine
comprehensive Pain Management Program
over a five-year period was completed.
Outcome measures were the Visual Analog
Scale Past Month Average Pain score (VASPMA), Multidimensional Pain Inventory pain
and interference scales (MPI-P and MPI-I),
and the Pain and Impairment Relationship
Scale (PAIRS). Patients were categorized by
smoking status into non-smoker or current
smoker groups. Wilcoxon tests were used
to compare the pre-scores, post-scores, and
post-minus-pre scores between smoking status
groups.
Results: The pre-treatment VAS-PMA and
MPI-P median scores were significantly
higher in the current smoker group (81.5 and
5.0, respectively) compared to the non-smoker
group (76.5 and 4.3, respectively), whereas
post-treatment median scores did not differ.
Furthermore, the current smoker group had
a significantly greater decrease on the MPI-P
from pre- to post-treatment (median=-2.0)
than the non-smoker group (median=-1.6).
In addition, smokers had a significantly
higher pre-treatment PAIRS score (73.5) than
nonsmokers (70), whereas post-treatment
scores did not differ.
Conclusion: Smokers and non-smokers
both benefit from the program, but smokers,
who report greater initial pain and stronger
beliefs about the association between pain and
functional impairment, may benefit more than
non-smokers.

Introduction
Patients with chronic pain often fail to find
relief with multiple types of medical and
surgical interventions and may be referred to
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comprehensive pain programs (CPP). These
intensive programs offer a multidisciplinary
approach that enables patients to better
manage their pain using psychological,
behavioral, and physical therapy techniques.
Treatment typically involves meeting
individually and in groups with psychologists,
physical therapists, nurses, and physicians
to learn strategies to maximize function
and better cope with pain. To date, there
have been few studies of patient factors that
correlate with CPP success.1,2 However,
smoking and its relationship to chronic pain
has long been studied, with smokers often
reporting a greater number of painful sites and
pain intensity compared to non-smokers.1,3
It is not known whether smoking status is
associated with outcomes in CPPs. One prior
study evaluated the relationship between
smoking status and outcomes among patients
who completed a CPP, finding a negative
association between smoking and employment
status after the program.4 There is a need for
more data regarding the impact of smoking
on CPP outcomes. A retrospective cohort
study was performed analyzing outcomes of
the Nebraska Medicine comprehensive Pain
Management Program over a five year period,
to identify if smoking status correlated with
treatment outcomes as measured by the Visual
Analog Scale (VAS), Multidimensional Pain
Inventory (MPI), and Pain and Impairment
Relationship Scale (PAIRS).5,6,7

scale to measure interference of pain in
relationships and daily activities.7

Methods

Admission criteria include pain that is chronic
and non-malignant; desire for non-invasive
pain treatment; stability of other medical
problems; no psychiatric hospitalizations,
suicide attempts, self-harm or harm to others
in the last three months; involvement of a
family member or significant other for a
one-time meeting; willingness to complete
an opiate medication taper with the goal
of remaining off opiate pain medication
in the long term; free of substance abuse
(illicit drugs, alcohol, misuse of prescription
medications); memory and concentration
adequate to benefit from classroom lectures;
5 minute walking tolerance; and ability
to complete a floor to standing transfer
independently. Patients may be referred by a
primary care or specialty physician, or may
be self-referred. Patients were not encouraged
to quit smoking as part of the program, due

Measures: Visual Analog Scale (VAS). The
VAS is a series of 10-centimeter lines with
descriptive anchors at each end (“No pain”
and “Pain at its worst”) on which patients
are asked to mark an “X” to represent their
average level of pain on a good day, bad day,
today, and over the past month, respectively.
The past month average pain level was
identified, a priori, for use in the current
study.6
Multidimensional Pain Inventory (MPI).
The MPI is a 61-item questionnaire with 13
subscales assessing the psychosocial impact
of chronic pain. Two subscales were identified
a priori for use in this study, namely the
“Pain” scale, to measure pain intensity and
pain-related suffering, and the “Interference”

Pain and Impairment Relationship
Scale (PAIRS). The PAIRS is a 15-item
questionnaire measuring the extent to which
patients believe their pain is associated with
their functional status or impairment. Each
item consists of a statement followed by a
7-point Likert scale on which patients indicate
their level of agreement or disagreement with
the statement (e.g., “I have come to accept
that I am a disabled person due to my chronic
pain.”).5
Procedures: The Nebraska Medicine Pain
Management Program is a multidisciplinary,
four-week, day-long treatment program,
designed to help individuals with chronic
non-malignant pain. Services are provided
in a multidisciplinary format by clinical
psychologists, physical therapists, a nurse,
and a pain physician. Assessment and
treatment services are comprehensive
and integrated. The primary purpose of
the program is to help patients cope more
effectively with pain-related problems and
maximize their functioning. Specifically,
treatment involves three components, which
occur simultaneously: Physical therapy,
psychological treatment, and medication
program/nursing, with the latter involving a
physician-monitored opioid tapering program
for patients who enter the program on opiates.
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to the additional stress this would entail
beyond that associated with the program
itself. However, for those motivated to quit,
the program helped develop a post- discharge
plan for smoking cessation.
Pre- and post-intervention scores on the Visual
Analog Scale past month average (VASPMA), Multidimensional Pain Inventory
pain and interference Scales (MPI-P, MPI-I),
and Pain and Impairment Relationship Scale
(PAIRS) were analyzed for patients over the
age of 19-years old who participated in the
Nebraska Medicine CPP from 2010 – 2015.
Institutional Review Board (IRB) approval
was obtained for the research. Smoking status
was determined via chart review as part of
a previous study.2 Former smokers were
excluded as the duration of time since they
had quit smoking was not established.
PC SAS version 9.4 software was used for
all analyses. Only subjects with complete
data (pre- and post- values on all paired data)
were included in the analyses. Demographic
variables, including gender, race, and marital
status, were examined for association with
smoking status using Chi-Square tests or
Fisher’s Exact Tests when cell counts were
low. Outcome measures were tested for
normality using the Wilks-Shapiro test. None
of the outcomes passed the test of normality;
thus, nonparametric Wilcoxon tests were
used to compare the pre- scores, post- scores,
and post-minus-pre scores between smoking
status groups. The median and quartiles are
presented. The outcome “program completed”
was compared between smoking groups using
a Fisher’s Exact Test.

Results
Tables 1 and 2 show basic demographic data.
A total of 178 patients were categorized by
smoking status into non-smokers (N=120)
and current smokers (N=58). The overall
population was 70% female and 30% male,
with 81% white and 19% non-white or
unknown. Table 1 shows the mean age of
the sample was 43.6 years, with a standard
deviation of 12.88 years. Table 2 contains
descriptive statistics and Chi-Square
or Fisher’s Exact Test p-values for the
comparison of smokers versus non-smokers
on each of the demographic variables. None
of the differences were statistically significant.
Table 3 shows descriptive statistics (median
and quartiles) and Wilcoxon p-values for
the pre-treatment, post-treatment, and postminus-pre VAS-PMA scores for current
smokers versus non-smokers. The pretreatment VAS-PMA median was significantly
higher in the current smoker group (81.5)
13 Original Reports

compared to the non-smoker group (76.5).
However, the post-treatment VAS-PMA was
not significantly different between current
smokers (median=52) and non-smokers
(median=53). The median difference (post –
pre) was not statistically significant between
the two groups.
Table 4 contains descriptive statistics (median
and quartiles) and Wilcoxon p-values for
the pre-treatment, post-treatment, and
post-minus-pre MPI-P scores for current
smokers versus non-smokers. Pre-treatment
MPI-P scores were significantly higher in the
current smoker group (median=5.0) versus
the non-smoker group (median=4.3). The
post-treatment median MPI-P score was
not significantly different between smoking
status groups. The current smoker group had
a significantly greater decrease from pre- to
post-treatment (median=-2.0) than the nonsmoker group (median=-1.6).
Table 5 shows descriptive statistics (median
and quartiles) and Wilcoxon p-values for the
pre-treatment, post-treatment, and post-minuspre MPI-I scores for current smokers versus
non-smokers. None of the differences were
statistically significant.
Table 6 contains descriptive statistics (median
and quartiles) and Wilcoxon p-values for
the pre-treatment, post-treatment, and postminus-pre PAIRS scores for current smokers
versus non-smokers. Pre-treatment PAIRS
scores were significantly higher in the current
smoker group (median=73.5) versus the nonsmoker group (median=70.0). There were no
statistically significant differences in the posttreatment PAIRS scores or the post-minus-pre
PAIRS scores.
Table 7 shows descriptive statistics for the
variable “program completed.” Two subjects
from the non-smoker group had missing data
for this variable and were not included in the
summary or analysis. In total, 97% of current
smokers completed the program compared
to 99% of non-smokers. The result was not
statistically significant.
Analyses were also performed to see if the
changes from pre to post were significant
within the smoking and non-smoking groups
separately, using Wilcoxon signed rank test.
The analyses within the two groups for each
variable, including difference between VAS,
Pain, Interference, and PAIRS, were all
statistically significant in both smoking and
non-smoking groups with a p-value less than
0.0001.

Discussion
Among the current sample of patients who
completed a 4-week CPP, current smokers
reported more pain at the start of the program
compared to nonsmokers, as revealed by
pre-treatment scores on both the VAS-PMA
and the MPI-P. This finding is consistent with
previous research reporting a greater number
of painful sites and higher pain intensity
among smokers compared to their non-smoker
counterparts.1,3 In addition to reporting greater
pain intensity prior to treatment, current
smokers in this study also reported stronger
beliefs about the association between their
pain and functional impairment compared
to non-smokers, as reflected in the PAIRS.
At the end of treatment, however, there
was no evidence for a significant difference
between groups in reports of pain, nor in the
association between pain and impairment.
The findings suggest that the program reduced
pain intensity, and the extent to which
patients believed their pain was associated
with functional status, to the same level for
both current smokers and non-smokers. In
connection with the significantly higher
pre-treatment pain scores as well as greater
post-minus-pre MPI-P scores among current
smokers compared to non-smokers, the results
suggest that not only do current smokers
benefit from the CPP but they may receive
greater benefit when compared with a nonsmoking cohort.

Conclusions
The Nebraska Medicine Pain Management
Program had a high completion rate from
2010 to 2015. Smokers and non-smokers
both appear to benefit from the program, and
smokers, who report greater initial pain, may
benefit more than non-smokers. Smokers
are excluded from some pain treatment
modalities; however, the data suggest that
smokers should not be excluded from CPPs.
Further studies should assess whether
adding smoking cessation counseling to
CPPs increases the magnitude of successful
outcomes. 
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Table 1.

Demographics (Gender, Race, Smoking History,
Marital Status, Age).
Frequency

Percent

Female

125

70.22

Male

53

29.78

Not White/Unknown

34

19.10

White

144

80.90

Gender

Race

Table 2.

Demographic variables N (%) and Chi-Square or Fisher’s Exact Test p-values.
Current Smoker

Non-Smoker

N=58

N=120

Gender (female)

38 (66%)

87 (73%)

0.3396

Race (white)

45 (78%)

99 (83%)

0.4344

Divorced/separated

12 (21%)

19 (16%)

Married/cohabiting

28 (50%)

67 (56%)

Single

14 (25%)

29 (24%)

2 (4%)

5 (4%)

Variable

Marital Status

Widowed/other/UNK

Smoking History
Current Smoker

58

32.58

Non-Smoker

120

67.42

Divorced/Separated

31

17.61

Married/Cohabitating

95

53.98

Single

43

24.43

Widowed/other/unk

7

3.98

Marital Status

P-value

0.8052

Table 3.
VAS-PMA (Visual Analog Scale past month average) median (quartiles) and Wilcoxon p-values.
Variable

Current Smoker

Non-Smoker

N=58

N=120

P-value

Pre VAS-PMA

81.5 (73, 92)

76.5 (66, 88)

0.0230

Age

Post VAS-PMA

52 (23, 75)

53 (35, 68)

0.7812

Mean: 43.63

Post—Pre VAS-PMA

-27 (-51, -7)

-23 (-39, -9)

0.4028

Std Dev: 12.88

Table 4.
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Multidimensional Pain Inventory pain scale (MPI-P) median (quartiles) and Wilcoxon p-values.
Current Smoker

Non-Smoker

N=58

N=120

Pre MPI-P

5.0 (4.0, 5.3)

4.3 (4.0, 5.0)

0.0214

Post MPI-P

2.5 (1.7, 3.7)

2.7 (2.0, 3.7)

0.3886

-2.0 (-3.0, -1.0)

-1.6 (-2.3, -0.7)

0.0362

Variable

Post—Pre MPI-P

P-value

Table 5.

Multidimensional Pain Inventory interference scale (MPI-I) median (quartiles) and Wilcoxon p-values.
Current Smoker

Non-Smoker

N=58

N=120

Pre MPI-I

4.95 (4.50, 5.50)

4.80 (4.15, 5.40)

0.1264

Post MPI-I

3.20 (1.80, 4.10)

3.20 (2.20, 4.10)

0.9122

-1.90 (-2.60, -0.70)

-1.30 (-2.30, -0.75)

0.2278

Variable

Post—Pre MPI-I

P-value

Table 6.

Pain and Impairment Relationship Scale (PAIRS) median (quartiles) and Wilcoxon p-values.
Current Smoker

Non-Smoker

N=58

N=120

Pre PAIRS

73.5 (67.0, 84.0)

70.0 (63.0, 79.0)

0.0386

Post PAIRS

45.5 (34.0, 63.0)

46.0 (37.5, 55.5)

0.9629

-26.0 (-40.0, -15.0)

-23.0 (-35.0, -14.0)

0.2961

Variable

Post—Pre PAIRS

P-value

Table 7.

Program Completed N (%) and Fisher’s Exact Test p-value
Variable
Program Completed
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Current Smoker

Non-Smoker

N=58

N=120

56 (97%)

117 (99%)

P-value
0.2529
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